Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04988386 · ClinicalTrials.gov registry record · Phase 3
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
A Phase 3 study of Amyloid Cardiomyopathy, Transthyretin-Related, sponsored by Eidos Therapeutics, a BridgeBio company.
- Active
- Registry status
- Phase 3
- Development phase
- 389
- Enrollment target
- 20
- Study locations
NCT04988386 is a Phase 3 study of Amyloid Cardiomyopathy, Transthyretin-Related that is active but no longer recruiting, run by Eidos Therapeutics, a BridgeBio company. The registered enrollment target is 389 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT04988386, a Phase 3 study of Amyloid Cardiomyopathy, Transthyretin-Related, is active but no longer recruiting, sponsored by Eidos Therapeutics, a BridgeBio company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 389 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Conditions Studied
Interventions
- DRUG Acoramidis (AG10)
Study Locations (20)
New York
- New York University Langone Health - New York
- Columbia University Irving Medical Center - New York
- Laurelton Heart Specialists - Rosedale
- Montefiore Medical Center at Hutchinson - The Bronx
Illinois
- Northwestern University - Chicago
- University of Chicago Medical Center - Chicago
- NorthShore University Health System - Evanston
Missouri
- Saint Luke's Hospital of Kansas City - Kansas City
- Washington University - St Louis
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
- University of Pittsburgh Medical Center (UPMC) - Pittsburgh
California
- Cedars-Sinai Medical Center - Los Angeles
Colorado
- University of Colorado Hospital - Anschutz Medical Campus - Aurora
Maryland
- MedStar Medical Group Cardiology at Franklin Square - Baltimore
Massachusetts
- Boston University Medical Center General Clinical Research Unit - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2028-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04988386
The ClinicalTrials.gov registry entry for NCT04988386 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eidos Therapeutics, a BridgeBio company, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloid Cardiomyopathy, Transthyretin-Related appearing as the primary indexed condition, and to 1 intervention - of which Acoramidis (AG10) is the first listed.
NCT04988386 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT04988386 about?
NCT04988386 is a clinical study titled "Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants". Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
What is the current status of trial NCT04988386?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 389 participants. The study started on 2021-10-27. Estimated completion is 2028-05-15.
What conditions does trial NCT04988386 study?
This clinical trial studies the following conditions: Amyloid Cardiomyopathy, Transthyretin-Related.
What interventions are being tested in trial NCT04988386?
The interventions under investigation include: Acoramidis (AG10) (DRUG).
Who is sponsoring clinical trial NCT04988386?
This trial is sponsored by Eidos Therapeutics, a BridgeBio company, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04988386 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.